Jump to main content
Jump to site search


The Effect of Crocetin Supplementation on Markers of Atherogenic Risk in Patients with Coronary Artery Disease: A Pilot, Randomized, Double-blind, Placebo-controlled Clinical Trial

Abstract

Background and Purpose. Molecular mechanisms of atherogenesis are considered emerging therapeutic targets for atherosclerosis prevention. Cell and animal studies have shown that crocetin can decelerate the atherogenesis. However, the anti-atherogenic properties of crocetin in human is still ambiguous. Methods and Results. Fifty clinically diagnosed CAD patients were randomly divided into two parallel groups: crocetin and placebo who received one capsule of crocetin (10 mg) and placebo per day, respectively, for two months. The serum circulating homocysteine (Hcy) [-1.09 (-1.64 to -0.54), P = 0.001], heart-type fatty acid binding protein (h-FABP) [-2.07 (-2.72 to -1.43), P = 0.001], intercellular adhesion molecule 1 [-14.92 (-21.92 to -7.92), P = 0.001], vascular cell adhesion molecule 1 [-18.61 (-29.73 to -7.49), P = 0.002], and monocyte chemoattractant protein 1 [-4.67 (-6.50 to -2.83), P = 0.001] decreased significantly after the trial in the crocetin group, while high-density lipoprotein (HDL) significantly increased [+4.21 (0.68 to 7.73), P = 0.021]. Also, systolic [-0.21 (-0.32 to -0.10), P= 0.001] and diastolic [-0.20 (-0.34 to -0.07), P= 0.004] blood pressures decreased significantly in the crocetin group. Nevertheless, the clinically significant change percents were only observed in Hcy (-15.25 ± 3.15), HDL (-10.70 ± 5.06), and h-FABP, (-21.10 ± 3.09) in the crocetin group. Furthermore, the relative increase in the gene expressions of sirtuin1 (and AMP-activated protein kinase, and decrease in the lectin-type oxidized LDL receptor 1 and nuclear factor-kappa B expression in isolated peripheral blood mononuclear cells in the crocetin group was significant at the end of the trial in comparison with the placebo. Conclusion. As the first human study, we showed the crocetin capacity to alter the expression of atherogenic genes and endothelial cell adhesion molecules in CAD patients. It appears that crocetin could be considered as the promising anti-atherogenic candidate for future studies.

Back to tab navigation

Publication details

The article was received on 02 Jun 2019, accepted on 30 Sep 2019 and first published on 05 Oct 2019


Article type: Paper
DOI: 10.1039/C9FO01166H
Food Funct., 2019, Accepted Manuscript

  •   Request permissions

    The Effect of Crocetin Supplementation on Markers of Atherogenic Risk in Patients with Coronary Artery Disease: A Pilot, Randomized, Double-blind, Placebo-controlled Clinical Trial

    S. Abedimanesh, Z. Bathai, A. Ostadrahimi, M. Asghari Jafarabadi and M. Taban Sadeghi, Food Funct., 2019, Accepted Manuscript , DOI: 10.1039/C9FO01166H

Search articles by author

Spotlight

Advertisements